X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (38667) 38667
Book Chapter (195) 195
Dissertation (51) 51
Conference Proceeding (24) 24
Newspaper Article (7) 7
Publication (7) 7
Magazine Article (6) 6
Government Document (4) 4
Paper (4) 4
Book / eBook (3) 3
Web Resource (3) 3
Book Review (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antitumor-activity (21880) 21880
humans (17718) 17718
antitumor activity (14122) 14122
cancer (11565) 11565
animals (11481) 11481
oncology (10612) 10612
mice (7636) 7636
apoptosis (7415) 7415
cell line, tumor (7017) 7017
pharmacology & pharmacy (6085) 6085
female (5728) 5728
antineoplastic agents - pharmacology (5726) 5726
tumors (5365) 5365
cytotoxicity (5190) 5190
anticancer properties (5159) 5159
biochemistry & molecular biology (4823) 4823
chemistry, medicinal (4525) 4525
male (4386) 4386
in-vitro (4257) 4257
chemotherapy (4163) 4163
analysis (3267) 3267
cell proliferation - drug effects (3244) 3244
chemistry, multidisciplinary (3176) 3176
antineoplastic agents - chemistry (3047) 3047
proteins (2976) 2976
care and treatment (2963) 2963
apoptosis - drug effects (2907) 2907
toxicity (2894) 2894
chemistry, organic (2859) 2859
expression (2820) 2820
immunotherapy (2816) 2816
derivatives (2800) 2800
antineoplastic agents - therapeutic use (2702) 2702
cancer therapies (2660) 2660
inhibition (2509) 2509
research (2374) 2374
neoplasms - drug therapy (2357) 2357
breast cancer (2356) 2356
cells (2351) 2351
in-vivo (2230) 2230
kinases (2189) 2189
therapy (2183) 2183
metastasis (2181) 2181
cell biology (2177) 2177
cell cycle (2174) 2174
structure-activity relationship (2162) 2162
medicine, research & experimental (2154) 2154
cell proliferation (2103) 2103
health aspects (2071) 2071
xenograft model antitumor assays (2058) 2058
antineoplastic agents - chemical synthesis (1996) 1996
cell survival - drug effects (1942) 1942
dose-response relationship, drug (1937) 1937
immunology (1909) 1909
activation (1892) 1892
drug screening assays, antitumor (1853) 1853
chemistry, inorganic & nuclear (1851) 1851
drugs (1838) 1838
mice, nude (1838) 1838
growth (1805) 1805
gene expression (1758) 1758
inhibitors (1747) 1747
middle aged (1743) 1743
molecular structure (1695) 1695
nanoparticles (1693) 1693
signal transduction (1656) 1656
flow cytometry (1597) 1597
mice, inbred balb c (1593) 1593
angiogenesis (1586) 1586
tumor cells, cultured (1578) 1578
aged (1574) 1574
xenografts (1568) 1568
antineoplastic agents (1567) 1567
ligands (1561) 1561
lymphocytes (1561) 1561
metastases (1554) 1554
drug delivery systems (1541) 1541
tumor cell lines (1524) 1524
lymphocytes t (1516) 1516
chemistry (1513) 1513
multidisciplinary sciences (1506) 1506
breast-cancer (1463) 1463
melanoma (1452) 1452
medicine (1437) 1437
cisplatin (1418) 1418
lung cancer (1418) 1418
clinical trials (1411) 1411
pharmacology (1401) 1401
phase-i (1400) 1400
adult (1380) 1380
biotechnology (1364) 1364
doxorubicin (1362) 1362
cell death (1352) 1352
biotechnology & applied microbiology (1337) 1337
synthesis (1330) 1330
antimitotic agents (1307) 1307
treatment outcome (1286) 1286
research article (1265) 1265
leukemia (1246) 1246
phosphorylation (1235) 1235
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38304) 38304
Japanese (695) 695
Chinese (422) 422
German (107) 107
French (86) 86
Spanish (73) 73
Portuguese (63) 63
Korean (34) 34
Russian (32) 32
Polish (30) 30
Croatian (8) 8
Czech (4) 4
Hungarian (4) 4
Slovak (2) 2
Slovenian (2) 2
Bosnian (1) 1
Breton (1) 1
Catalan (1) 1
Indonesian (1) 1
Italian (1) 1
Latin (1) 1
Romanian (1) 1
Serbian (1) 1
Turkish (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2018, Volume 24, Issue 6, pp. 724 - 730
Journal Article
Cancer discovery, ISSN 2159-8290, 2012, Volume 2, Issue 3, pp. 227 - 235
BRAF mutations occur in 10% to 15% of colorectal cancers and confer adverse outcome in the metastatic setting. Although RAF inhibitors such as vemurafenib... 
CELLS | CETUXIMAB | MELANOMA | ONCOLOGY | KINASE | MUTATION | RESISTANCE | WILD-TYPE BRAF | KRAS | ANTITUMOR-ACTIVITY | MEK INHIBITORS
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2018, Volume 359, Issue 6377, pp. 770 - 775
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2018, Volume 36, Issue 6, pp. 572 - 580
PurposeMeasures of response that are clinically meaningful and occur early are an unmet need in metastatic castration-resistant prostate cancer clinical... 
MULTICENTER | PLUS PREDNISONE | THERAPY | ONCOLOGY | PROGNOSIS | DOUBLE-BLIND | ABIRATERONE ACETATE | ANTITUMOR-ACTIVITY | DOCETAXEL | CHEMOTHERAPY | ORIGINAL REPORTS
Journal Article
Chemical science (Cambridge), ISSN 2041-6539, 2018, Volume 9, Issue 4, pp. 790 - 810
The folate receptor (FR) is an important biomarker for many cancers, and its overexpression on tumours can be exploited for targeted therapy, diagnosis and... 
PHASE-II TRIAL | TUMOR-THERAPY | IN-VIVO | BIOLOGICAL EVALUATION | OVARIAN-CANCER | SPECTROSCOPIC PROBES | ANTITUMOR-ACTIVITY | NEW-GENERATION | FOLIC-ACID | PRECLINICAL EVALUATION | CHEMISTRY, MULTIDISCIPLINARY | Conjugates | Imaging | Vitamin B | Diagnostic software | Biomarkers | Antibodies | Diagnostic systems | Nanotechnology
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 1, p. e0192090
[This corrects the article DOI: 10.1371/journal.pone.0184816.]. 
Oncolysis | Antitumor activity | Cytokines | Anticancer properties
Journal Article
The Journal of clinical investigation, ISSN 1558-8238, 2017, Volume 127, Issue 9, pp. 3462 - 3471
Journal Article
Scientific reports, ISSN 2045-2322, 03/2018, Volume 8, Issue 1, pp. 5266 - 1
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper. 
Antitumor activity
Journal Article
Molecular therapy, ISSN 1525-0016, 2017, Volume 25, Issue 9, pp. 2214 - 2224
Targeting disialoganglioside (GD2) on neuroblastoma (NB) with T cells expressing a first-generation chimeric antigen receptor (CAR) was safe, but the cells had... 
neuroblastoma | GD2-CAR | immunotherapy | MEDICINE, RESEARCH & EXPERIMENTAL | NKT CELLS | ANTI-GD2 ANTIBODY | ANTITUMOR-ACTIVITY | THERAPY | IMMUNOTHERAPY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | TUMOR-ASSOCIATED MACROPHAGES | SUPPRESSOR-CELLS | BLOCKADE | ANTIGEN RECEPTOR | STAGE 4 NEUROBLASTOMA | Antineoplastic Agents, Immunological - administration & dosage | Humans | Child, Preschool | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Neuroblastoma - mortality | Neuroblastoma - therapy | Lymphocyte Depletion | Molecular Targeted Therapy | Recombinant Fusion Proteins | Young Adult | T-Lymphocytes - metabolism | Neuroblastoma - immunology | Female | Child | Neuroblastoma - pathology | Cytokines - blood | Immunotherapy, Adoptive - adverse effects | Immunotherapy, Adoptive - methods | Receptors, Antigen, T-Cell - metabolism | Treatment Outcome | Combined Modality Therapy | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Adolescent | Lymphocyte Count | Myeloid Cells - metabolism | T-Lymphocytes - immunology | Receptors, Antigen, T-Cell - genetics | Transplantation Conditioning | Cohort Studies | Antigens | Lymphatic system | Myeloid cells | CD11b antigen | PD-1 protein | Lymphocytes T | Neuroblastoma | Metastasis | Patients | Fever | CD45 antigen | Blood | CD163 antigen | Cyclophosphamide | Pain | Fludarabine | Lymphocytes | Bone marrow | Antitumor activity | Movement disorders | Apoptosis | Neutropenia | Original
Journal Article
by Arce Vargas, Frederick and Furness, Andrew J.S and Solomon, Isabelle and Joshi, Kroopa and Mekkaoui, Leila and Lesko, Marta H and Miranda Rota, Enrique and Dahan, Rony and Georgiou, Andrew and Sledzinska, Anna and Ben Aissa, Assma and Franz, Dafne and Werner Sunderland, Mariana and Wong, Yien Ning Sophia and Henry, Jake Y and O’Brien, Tim and Nicol, David and Challacombe, Ben and Beers, Stephen A and Turajlic, Samra and Gore, Martin and Larkin, James and Swanton, Charles and Chester, Kerry A and Pule, Martin and Ravetch, Jeffrey V and Marafioti, Teresa and Peggs, Karl S and Quezada, Sergio A and Spain, Lavinia and Wotherspoon, Andrew and Francis, Nicholas and Smith, Myles and Strauss, Dirk and Hayes, Andrew and Soultati, Aspasia and Stares, Mark and Lynch, Joanna and Fotiadis, Nicos and Fernando, Archana and Hazell, Steve and Chandra, Ashish and Pickering, Lisa and Rudman, Sarah and Chowdhury, Simon and Jamal-Hanjani, Mariam and Veeriah, Selvaraju and Shafi, Seema and Czyzewska-Khan, Justyna and Johnson, Diana and Laycock, Joanne and Bosshard-Carter, Leticia and Goh, Gerald and Rosenthal, Rachel and Gorman, Pat and Murugaesu, Nirupa and Hynds, Robert E and Wilson, Gareth and Birkbak, Nicolai J and Watkins, Thomas B.K and McGranahan, Nicholas and Horswell, Stuart and Mitter, Richard and Escudero, Mickael and Stewart, Aengus and Van Loo, Peter and Rowan, Andrew and Xu, Hang and Hiley, Crispin and Abbosh, Christopher and Goldman, Jacki and Stone, Richard Kevin and Denner, Tamara and Matthews, Nik and Elgar, Greg and Ward, Sophia and Biggs, Jennifer and Costa, Marta and Begum, Sharmin and Phillimore, Ben and Chambers, Tim and Nye, Emma and Graca, Sofia and Al Bakir, Maise and Hartley, John A and Lowe, Helen L and Herrero, Javier and Lawrence, David and Hayward, Martin and Panagiotopoulos, Nikolaos and Kolvekar, Shyam and Falzon, Mary and Borg, Elaine and Simeon, Celia and Hector, Gemma and Smith, Amy and Aranda, Marie and Novelli, Marco and Oukrif, Dahmane and Janes, Sam M and ... and Melanoma TRACERx Consortium and Renal TRACERx Consortium and Lung TRACERx Consortium
Immunity (Cambridge, Mass.), ISSN 1074-7613, 2017, Volume 46, Issue 4, pp. 577 - 586
CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies... 
regulatory T cells | tumor immunotherapy | anti-CD25 | Treg depletion | inhibitory Fc receptor | CD25 | tumor microenvironment | Fc gamma receptors | anti-PD-1 | EFFECTOR | RESPONSES | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | CANCER-PATIENTS | MELANOMA | MONOCLONAL-ANTIBODY | ANTI-CTLA-4 ANTIBODIES | IMMUNOLOGY | ANTITUMOR-ACTIVITY | COMBINATION | GAMMA-RS | T-Lymphocytes, Regulatory - metabolism | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Lymphocyte Depletion | Receptors, IgG - metabolism | T-Lymphocytes, Regulatory - immunology | Neoplasms - therapy | Flow Cytometry | Immunoglobulin Fc Fragments - immunology | Antibodies, Monoclonal - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Kaplan-Meier Estimate | Programmed Cell Death 1 Receptor - metabolism | Receptors, IgG - immunology | Protein Binding - immunology | Animals | Neoplasms - immunology | K562 Cells | Cell Line, Tumor | Mice | Antibodies, Monoclonal - metabolism | Programmed Cell Death 1 Receptor - immunology | Neoplasms - pathology | Viral antibodies | Cell death | Analysis | Immunotherapy | Antibodies | T cells | Cancer | Fc receptors | Beer | Immunoglobulins | Lymphatic system | Immune response | Cytokines | Melanoma | Light emitting diodes | Lymphocytes T | Anticancer properties | Depletion | Lymphocytes | Tumors | Immune system | Report
Journal Article